These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Journal Abstract Search

277 related items for PubMed ID: 21819519

  • 1.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 2.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 3.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 4. An update on the clinical development of dalcetrapib (RO4607381), a cholesteryl ester transfer protein modulator that increases HDL cholesterol levels.
    Rhainds D, Arsenault BJ, Brodeur MR, Tardif JC.
    Future Cardiol; 2012 Jul; 8(4):513-31. PubMed ID: 22871191
    [Abstract] [Full Text] [Related]

  • 5.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 6. Effect of dalcetrapib plus pravastatin on lipoprotein metabolism and high-density lipoprotein composition and function in dyslipidemic patients: results of a phase IIb dose-ranging study.
    Ballantyne CM, Miller M, Niesor EJ, Burgess T, Kallend D, Stein EA.
    Am Heart J; 2012 Mar; 163(3):515-21, 521.e1-3. PubMed ID: 22424025
    [Abstract] [Full Text] [Related]

  • 7.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 8. Comparative long-term efficacy and tolerability of pitavastatin 4 mg and atorvastatin 20-40 mg in patients with type 2 diabetes mellitus and combined (mixed) dyslipidaemia.
    Gumprecht J, Gosho M, Budinski D, Hounslow N.
    Diabetes Obes Metab; 2011 Nov; 13(11):1047-55. PubMed ID: 21812889
    [Abstract] [Full Text] [Related]

  • 9. Cholesteryl ester transfer-protein modulator and inhibitors and their potential for the treatment of cardiovascular diseases.
    Shinkai H.
    Vasc Health Risk Manag; 2012 Nov; 8():323-31. PubMed ID: 22661899
    [Abstract] [Full Text] [Related]

  • 10. Targeting residual cardiovascular risk: raising high-density lipoprotein cholesterol levels.
    Hausenloy DJ, Yellon DM.
    Heart; 2008 Jun; 94(6):706-14. PubMed ID: 18480348
    [Abstract] [Full Text] [Related]

  • 11. Long-term (18-month) efficacy of atorvastatin therapy in type 2 diabetics at cardiovascular risk.
    Velussi M.
    Nutr Metab Cardiovasc Dis; 2002 Feb; 12(1):29-35. PubMed ID: 12125227
    [Abstract] [Full Text] [Related]

  • 12. Safety and tolerability of dalcetrapib.
    Stein EA, Stroes ES, Steiner G, Buckley BM, Capponi AM, Burgess T, Niesor EJ, Kallend D, Kastelein JJ.
    Am J Cardiol; 2009 Jul 01; 104(1):82-91. PubMed ID: 19576325
    [Abstract] [Full Text] [Related]

  • 13. Distinct effects of pitavastatin and atorvastatin on lipoprotein subclasses in patients with Type 2 diabetes mellitus.
    Shimabukuro M, Higa M, Tanaka H, Shimabukuro T, Yamakawa K, Masuzaki H.
    Diabet Med; 2011 Jul 01; 28(7):856-64. PubMed ID: 21244474
    [Abstract] [Full Text] [Related]

  • 14. Low-density lipoprotein cholesterol reduction and goal achievement with ezetimibe/simvastatin versus atorvastatin or rosuvastatin in patients with diabetes, metabolic syndrome, or neither disease, stratified by National Cholesterol Education Program risk category.
    Polis AB, Abate N, Catapano AL, Ballantyne CM, Davidson MH, Smugar SS, Tershakovec AM.
    Metab Syndr Relat Disord; 2009 Dec 01; 7(6):601-10. PubMed ID: 19929597
    [Abstract] [Full Text] [Related]

  • 15.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 16.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 17. What is the most effective strategy for managing diabetic dyslipidaemia?
    Reasner CA.
    Atheroscler Suppl; 2005 Sep 01; 6(3):21-7. PubMed ID: 16054442
    [Abstract] [Full Text] [Related]

  • 18. Vascular effects and safety of dalcetrapib in patients with or at risk of coronary heart disease: the dal-VESSEL randomized clinical trial.
    Lüscher TF, Taddei S, Kaski JC, Jukema JW, Kallend D, Münzel T, Kastelein JJ, Deanfield JE, dal-VESSEL Investigators.
    Eur Heart J; 2012 Apr 01; 33(7):857-65. PubMed ID: 22345126
    [Abstract] [Full Text] [Related]

  • 19. Dalcetrapib , a cholesteryl ester transfer protein modulator.
    Hooper AJ, Burnett JR.
    Expert Opin Investig Drugs; 2012 Sep 01; 21(9):1427-32. PubMed ID: 22725099
    [Abstract] [Full Text] [Related]

  • 20. 'Trig-onometry': non-high-density lipoprotein cholesterol as a therapeutic target in dyslipidaemia.
    Jacobson TA.
    Int J Clin Pract; 2011 Jan 01; 65(1):82-101. PubMed ID: 21105969
    [Abstract] [Full Text] [Related]

    Page: [Next] [New Search]
    of 14.